Evaluation_NN of_IN a_DT Novel_NP Commercial_NP Enzyme-Linked_NP Immunosorbent_NP Assay_NP Detecting_NP Coxiella_NP burnetii-Specific_JJ Immunoglobulin_NP G_NP for_IN Q_NP Fever_NP Prevaccination_NP Screening_NP and_CC Diagnosis_NP A_DT novel_NN commercially_RB available_JJ enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) for_IN prevaccination_NN screening_NN and_CC diagnosis_NN of_IN Q_NP fever_NN (_( PanBio_NP Coxiella_NP burnetii_NP immunoglobulin_NN G_NP [_SYM IgG_NP ]_SYM ELISA_NP )_) was_VBD compared_VBN to_TO the_DT complement_NN fixation_NN test_NN (_( CFT_NP )_) ,_, and_CC the_DT indirect_JJ fluorescent-antibody_NN test_NN (_( IFAT_NP )_) was_VBD used_VBN to_TO resolve_VB discrepant_JJ results_NNS between_IN the_DT other_JJ two_CD tests_NNS ._SENT A_DT total_NN of_IN 214_CD serum_NN samples_NNS was_VBD tested_VBN ._SENT The_DT ELISA_NP demonstrated_VBD a_DT specificity_NN of_IN 96_CD %_NN (_( 46_CD of_IN 48_CD samples_NNS )_) and_CC a_DT sensitivity_NN of_IN 71_CD %_NN (_( 95_CD of_IN 134_CD samples_NNS )_) ._SENT Of_IN the_DT six_CD serum_NN pairs_NNS showing_VBG CFT_NP seroconversion_NN ,_, three_CD pairs_NNS showed_VBD a_DT corresponding_JJ ELISA_NP seroconversion_NN ._SENT No_DT cross-reactivity_NN was_VBD observed_VBN in_IN the_DT ELISA_NP with_IN serum_NN samples_NNS from_IN patients_NNS with_IN mycoplasma_NN ,_, brucella_NN ,_, and_CC chlamydia_NP infections_NNS ._SENT One_CD of_IN the_DT 13_CD patients_NNS with_IN leptospirosis_NN demonstrated_VBD a_DT positive_JJ result_NN in_IN the_DT ELISA_NP but_CC not_RB in_IN the_DT CFT_NP or_CC the_DT IFAT_NP ,_, and_CC Legionella_NP pneumophila_NP serogroup_NN 4_CD antibody_NN was_VBD found_VBN in_IN one_CD of_IN the_DT two_CD sera_NN that_WDT were_VBD false-positive_JJ by_IN ELISA_NP ._SENT The_DT results_NNS presented_VBN in_IN this_DT study_NN suggest_VBP that_IN the_DT PanBio_NP Q_NP fever_NN IgG_NP ELISA_NP is_VBZ a_DT specific_JJ alternative_JJ method_NN for_IN prevaccination_NN testing_NN and_CC an_DT aid_NN for_IN the_DT diagnosis_NN of_IN Q_NP fever_NN ._SENT This_DT test_NN is_VBZ suitable_JJ for_IN use_NN as_IN a_DT screening_NN assay_NN ,_, with_IN CFT_NP and/or_CC IFAT_NP used_VBD to_TO confirm_VB negative_JJ results_NNS ._SENT Q_NP fever_NN is_VBZ the_DT most_RBS common_JJ occupational_JJ zoonotic_JJ disease_NN of_IN livestock_NN handlers_NNS and_CC abattoir_NN workers_NNS in_IN Australia_NP ._SENT The_DT disease_NN is_VBZ usually_RB acquired_VBN by_IN inhalation_NN of_IN contaminated_JJ aerosols_NNS from_IN animals_NNS ,_, mainly_RB cattle_NNS ,_, sheep_NN ,_, and_CC goats_NNS ,_, infected_VBN with_IN the_DT causative_JJ agent_NN ,_, Coxiella_NP burnetii_NP ._SENT Q_NP fever_NN usually_RB presents_VBZ as_IN an_DT influenza-like_JJ illness_NN ,_, but_CC asymptomatic_JJ infection_NN and_CC shedding_VBG of_IN the_DT organism_NN into_IN products_NNS of_IN conception_NN may_MD occur_VB ._SENT Occasionally_RB ,_, a_DT chronic_JJ disease_NN form_NN ,_, subacute_JJ endocarditis_NN ,_, may_MD develop_VB months_NNS or_CC years_NNS later_RBR ._SENT Other_JJ chronic_JJ complications_NNS are_VBP granulomatous_JJ changes_NNS in_IN liver_NN ,_, lesions_NNS in_IN other_JJ organs_NNS ,_, and_CC the_DT post-Q_NP fever_NN fatigue_NN syndrome_NN ._SENT Due_JJ to_TO possible_JJ severe_JJ local_JJ or_CC systemic_JJ reactions_NNS ,_, prevaccination_NN screening_NN to_TO assess_VB prior_JJ exposure_NN before_IN vaccination_NN is_VBZ mandatory_JJ for_IN occupational_JJ groups_NNS at_IN risk_NN of_IN Q_NP fever_NN infection_NN ._SENT Adverse_JJ reactions_NNS are_VBP rare_JJ (_( <0.05%)_in =1.0_NN ;_: a_DT negative_JJ sample_NN had_VBD a_DT ratio_NN of_IN <1.0._IFAT =75_JJ %_NN fixation_NN was_VBD defined_VBN as_IN the_DT endpoint_NN ._SENT A_DT positive_JJ result_NN was_VBD defined_VBN as_IN having_VBG an_DT endpoint_NN titer_NN of_IN >=2.5_NN for_IN prevaccination_NN sera_NN and_CC >=4.0_NN for_IN diagnostic_JJ specimens_NNS ._SENT Analysis_NN of_IN variation_NN was_VBD used_VBN to_TO compare_VB the_DT mean_JJ ELISA_NP ratios_NNS for_IN different_JJ CFT_NP titers_NNS ._SENT Receiver_NN operator_NN curve_NN (_( ROC_NP )_) analysis_NN was_VBD performed_VBN to_TO compare_VB sensitivity_NN and_CC specificity_NN at_IN different_JJ cutoff_NN values_NNS ._SENT The_DT cutoff_NN for_IN optimal_JJ assay_NN performance_NN was_VBD determined_VBN by_IN using_VBG two-graph_NN ROC_NP analysis_NN ._SENT Statistics_NNS were_VBD performed_VBN by_IN using_VBG InstatR_NP (_( Graphpad_NP Software_NP Inc._NP ,_, San_NP Diego_NP ,_, Calif._NP )_) ._SENT Of_IN the_DT 214_CD serum_NN samples_NNS ,_, 184_CD were_VBD tested_VBN in_IN the_DT Q_NP fever_NN CFT_NN with_IN phase_NN II_NP antigen_NN ._SENT These_DT included_VBD all_DT sera_NN submitted_VBN for_IN investigation_NN of_IN Q_NP fever_NN immunity_NN and_CC infection_NN and_CC two_CD positive_JJ sera_NN from_IN the_DT specificity_NN panel_NN ._SENT Any_DT serum_NN that_WDT showed_VBD discrepant_JJ results_NNS was_VBD retested_VBN by_IN ELISA_NP and_CC tested_VBN in_IN the_DT Q_NP fever_NN phase_NN II_NP IgG_NP IFAT_NP ,_, which_WDT is_VBZ the_DT reference_NN method_NN ._SENT In_IN those_DT samples_NNS with_IN conflicting_VBG CFT_NP and_CC IFAT_NP results_NNS ,_, the_DT latter_NN was_VBD used_VBN to_TO classify_VB the_DT sample_NN ._SENT A_DT CFT_NP antibody_NN titer_NN of_IN 2.5_CD or_CC greater_JJR ,_, a_DT positive_JJ IgG_NP IFAT_NP result_NN with_IN a_DT titer_NN of_IN 10_CD or_CC greater_JJR ,_, and_CC a_DT positive_JJ IgG_NP ELISA_NP result_NN against_IN phase_NN II_NP antigen_NN are_VBP suggestive_JJ of_IN recent_JJ or_CC past_JJ infection_NN ._SENT In_IN the_DT comparison_NN with_IN the_DT CFT_NP ,_, and_CC with_IN the_DT use_NN of_IN IFAT_NP as_IN the_DT reference_NN method_NN to_TO classify_VB discrepant_JJ results_NNS ,_, the_DT Q_NP fever_NN IgG_NP ELISA_NP was_VBD found_VBN to_TO have_VB a_DT specificity_NN of_IN 96_CD %_NN ._SENT In_IN contrast_NN ,_, the_DT sensitivity_NN was_VBD only_RB 71_CD %_NN ._SENT This_DT low_JJ sensitivity_NN means_VBZ that_IN ,_, if_IN the_DT ELISA_NP is_VBZ used_VBN for_IN Q_NP fever_NN prevaccination_NN screening_NN ,_, then_RB there_EX is_VBZ a_DT risk_NN that_IN some_DT meat_NN workers_NNS who_WP have_VBP a_DT negative_JJ Q_NP fever_NN IgG_NP ELISA_NP result_NN ,_, and_CC in_IN whom_WP the_DT skin_NN test_NN is_VBZ also_RB negative_JJ ,_, may_MD be_VB inadvertently_RB vaccinated_VBN ._SENT Such_JJ vaccinees_NNS have_VBP a_DT low_JJ risk_NN of_IN developing_VBG a_DT severe_JJ local_JJ or_CC systemic_JJ reaction_NN ._SENT The_DT combined_JJ prevaccination_NN antibody_NN and_CC skin_NN test_NN is_VBZ not_RB an_DT absolute_JJ test_NN of_IN immunity_NN ._SENT It_PP is_VBZ done_VBN primarily_RB to_TO exclude_VB those_DT individuals_NNS who_WP may_MD develop_VB severe_JJ reactions_NNS when_WRB vaccinated_VBN at_IN the_DT inoculation_NN site_NN ._SENT Minor_JJ or_CC threshold_NN levels_NNS of_IN immunity_NN or_CC sensitization_NN to_TO C._NP burnetii_NP may_MD not_RB be_VB detected_VBN by_IN the_DT serological_JJ and_CC skin_NN tests_NNS but_CC only_RB by_IN lymphocyte_NN stimulation_NN testing_NN ._SENT TABLE_NN 1_CD |_SYM Comparison_NN of_IN Q_NP fever_NN CFT_NP and_CC IFAT_NP with_IN PanBio_NP IgG_NP ELISA_NP (_( n_NN =_SYM 182_CD )_) A_DT correlation_NN was_VBD shown_VBN between_IN the_DT individual_JJ Q_NP fever_NN IgG_NP ELISA_NP assay_NN values_NNS and_CC the_DT CFT_NP results_NNS with_IN the_DT sera_NN submitted_VBN for_IN prevaccination_NN screening_VBG (_( r_LS =_SYM 0.634_CD ,_, P_NN <_SYM 0.0001_CD )_) and_CC for_IN investigation_NN of_IN active_JJ infection_NN (_( r_LS =_SYM 0.2965_CD ,_, P_NN =_SYM 0.0012_CD )_) ._SENT An_DT analysis_NN of_IN the_DT distribution_NN of_IN index_NN values_NNS in_IN the_DT ELISA_NP showed_VBD that_IN 28_CD of_IN the_DT 39_CD sera_NN (_( 71.8_CD %_NN )_) with_IN false-negative_JJ ELISA_NP results_NNS had_VBD absorbance_NN values_NNS within_IN 50_CD %_NN of_IN the_DT cutoff_NN ._SENT However_RB ,_, lowering_VBG the_DT cutoff_NN ratio_NN of_IN the_DT ELISA_NP below_IN 1.0_CD (_( F_NN value_NN ,_, 166.73_CD )_) did_VBD not_RB significantly_RB improve_VB its_PP$ performance_NN ._SENT Although_IN the_DT highest_JJS F_NN value_NN (_( 174.50_CD )_) was_VBD obtained_VBN with_IN a_DT cutoff_NN of_IN 0.7_CD ,_, the_DT specificity_NN was_VBD reduced_VBN to_TO 91.7_CD %_NN ._SENT As_IN the_DT specificity_NN of_IN the_DT test_NN is_VBZ clinically_RB more_RBR important_JJ in_IN prevaccination_NN screening_NN ,_, it_PP is_VBZ preferable_JJ to_TO use_VB a_DT cutoff_NN of_IN 1.0_CD or_CC 0.9_CD ,_, which_WDT results_VBZ in_IN a_DT specificity_NN of_IN 96_CD %_NN and_CC a_DT sensitivity_NN of_IN 71_CD or_CC 77_CD %_NN ,_, respectively_RB ._SENT The_DT low_JJ sensitivity_NN of_IN the_DT IgG_NP ELISA_NP for_IN the_DT diagnosis_NN of_IN recent_JJ infection_NN using_VBG paired_VBN sera_NN is_VBZ of_IN lesser_JJR concern_NN ._SENT This_DT is_VBZ because_IN the_DT formation_NN of_IN IgM_NP antibodies_NNS is_VBZ transient_JJ and_CC may_MD precede_VB that_IN of_IN IgG_NP antibodies_NNS ;_: consequently_RB ,_, a_DT specific_JJ IgM_NP IFAT_NP or_CC IgM_NP ELISA_NP is_VBZ preferable_JJ for_IN the_DT diagnosis_NN of_IN Q_NP fever_NN infection_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Comparison_NP of_IN Q_NP fever_NN IgG_NP ELISA_NP ratios_NNS with_IN CFT_NP titers_NNS in_IN sera_NN for_IN prevaccination_NN screening_NN (_( A_NP )_) and_CC investigation_NN of_IN Q_NP fever_NN infection_NN (_( B_NP )_) ._SENT Comparison_NN of_IN Q_NP fever_NN IgG_NP ELISA_NP ratios_NNS with_IN CFT_NP titers_NNS in_IN sera_NN for_IN prevaccination_NN screening_NN (_( A_NP )_) and_CC investigation_NN of_IN Q_NP fever_NN infection_NN (_( B_NP )_) ._SENT Mean_VB ELISA_NP ratios_NNS are_VBP shown_VBN by_IN horizontal_JJ bars_NNS ._SENT The_DT cutoff_NN values_VBZ (_( ratio_NN =_SYM 1.0_CD )_) are_VBP shown_VBN by_IN broken_VBN lines_NNS ._SENT Note_NN that_IN in_IN panel_NN A_DT two_CD sera_NN that_WDT had_VBD CFT_NN titers_NNS of_IN <2.5_had =10_NN and_CC that_IN in_IN panel_NN B_NP one_CD serum_NN sample_NN that_WDT had_VBD a_DT CFT_NP titer_NN of_IN <4.0_had =10_NN ._SENT pos_NNS ,_, positive_JJ ._SENT Of_IN the_DT six_CD serum_NN pairs_NNS showing_VBG CFT_NP seroconversion_NN or_CC rising_VBG titers_NNS ,_, three_CD pairs_NNS showed_VBD a_DT corresponding_JJ ELISA_NP seroconversion_NN ._SENT TABLE_NN 2_CD |_SYM Detection_NN of_IN Q_NP fever_NN in_IN six_CD paired_VBN sera_NN No_DT cross-reactivity_NN was_VBD observed_VBN in_IN the_DT ELISA_NP with_IN serum_NN samples_NNS from_IN patients_NNS with_IN mycoplasma_NN ,_, brucella_NN ,_, and_CC chlamydia_NP infections_NNS ._SENT However_RB ,_, cross-reactivity_NN was_VBD suggested_VBN in_IN a_DT sample_NN from_IN one_CD of_IN the_DT 13_CD patients_NNS with_IN Leptospira_NP interrogans_NNS serovar_JJ Pomona_NP infection_NN ,_, which_WDT gave_VBD a_DT false-positive_JJ ELISA_NP result_NN ._SENT Samples_NNS from_IN one_CD patient_NN with_IN confirmed_JJ Mycoplasma_NP pneumoniae_NNS infection_NN and_CC one_CD with_IN confirmed_JJ Leptospira_NP interrogans_NNS serovar_JJ Hardjo_NP infection_NN were_VBD repeatedly_RB ELISA_NP reactive_JJ and_CC were_VBD confirmed_VBN to_TO be_VB positive_JJ by_IN CFT_NP and_CC IFAT_NP ._SENT This_DT suggests_VBZ that_IN these_DT patients_NNS had_VBD past_JJ Q_NP fever_NN infections_NNS ._SENT In_IN a_DT recent_JJ study_NN of_IN the_DT PanBio_NP Leptospira_NP IgM_NP ELISA_NP ,_, sera_NN from_IN 3_CD of_IN 34_CD patients_NNS with_IN Q_NP fever_NN infections_NNS were_VBD reactive_JJ ,_, although_IN it_PP could_MD not_RB be_VB determined_VBN whether_IN this_DT was_VBD due_JJ to_TO cross-reactivity_NN or_CC persistent_JJ antibody_NN from_IN a_DT past_JJ leptospiral_JJ infection_NN ._SENT Legionella_NP pneumophila_NP serogroup_NN 4_CD antibody_NN was_VBD found_VBN in_IN one_CD of_IN the_DT two_CD sera_NN giving_VBG false-positive_JJ ELISA_NP results_NNS ._SENT This_DT may_MD represent_VB cross-reactivity_NN ,_, as_IN certain_JJ C._NP burnetii_NN epitopes_NNS have_VBP extensive_JJ homology_NN with_IN proteins_NNS from_IN other_JJ prokaryotes_NNS ._SENT Further_JJR studies_NNS with_IN larger_JJR sample_NN sizes_NNS are_VBP needed_VBN to_TO validate_VB these_DT preliminary_JJ findings_NNS ._SENT The_DT frequency_NN distribution_NN of_IN the_DT absorbance_NN ratios_NNS was_VBD not_RB bimodal_JJ and_CC showed_VBD no_DT clear_JJ discrimination_NN between_IN positive_JJ and_CC negative_JJ ELISA_NP values_NNS ._SENT The_DT dynamic_JJ range_NN of_IN positive_JJ ELISA_NP values_NNS was_VBD largely_RB restricted_VBN to_TO samples_NNS with_IN lower_JJR absorbance_NN ratios_NNS (_( between_IN 1.0_CD and_CC 2.64_CD )_) ,_, which_WDT suggests_VBZ that_IN some_DT positive_JJ values_NNS could_MD be_VB incorrectly_RB categorized_VBN as_IN negative_JJ ._SENT Some_DT changes_NNS to_TO the_DT ELISA_NP components_NNS may_MD be_VB needed_VBN to_TO improve_VB the_DT bimodal_JJ distribution_NN of_IN positive_JJ and_CC negative_JJ values_NNS and_CC extend_VB the_DT dynamic_JJ range_NN of_IN positive_JJ values_NNS ._SENT FIG._NN 2_CD ._SENT |_SYM Frequency_NN distribution_NN of_IN PanBio_NP Q_NP fever_NN IgG_NP ELISA_NP absorbance_NN ratios_NNS ._SENT Frequency_NN distribution_NN of_IN PanBio_NP Q_NP fever_NN IgG_NP ELISA_NP absorbance_NN ratios_NNS ._SENT Absorbance_NN ratios_NNS of_IN <=1.0_are =1.0_NN are_VBP positive_JJ (_( open_JJ columns_NNS )_) ._SENT The_DT results_NNS presented_VBN in_IN this_DT study_NN suggest_VBP that_IN the_DT PanBio_NP Q_NP fever_NN IgG_NP ELISA_NP is_VBZ a_DT specific_JJ alternative_JJ method_NN for_IN prevaccination_NN testing_NN and_CC the_DT diagnosis_NN of_IN Q_NP fever_NN ._SENT It_PP provides_VBZ a_DT standardized_JJ method_NN with_IN a_DT total_JJ incubation_NN time_NN of_IN 70_CD min_NN ,_, is_VBZ suitable_JJ for_IN large-scale_JJ screening_NN ,_, and_CC has_VBZ the_DT potential_NN for_IN automation_NN ._SENT However_RB ,_, this_DT test_NN is_VBZ suitable_JJ as_IN a_DT screening_NN assay_NN provided_VBD that_IN CFT_NP and/or_CC IFAT_NP is_VBZ used_VBN to_TO confirm_VB negative_JJ results_NNS ._SENT 